Table 1 (abstract P22). Effect of erenumab in patients achieving ≥50% response in MMDs vs non-responders and overall population
Outcome measures | Erenumab 70 mg | Erenumab 140 mg | ||||
|---|---|---|---|---|---|---|
≥50% Responders (N=75) | Non-responders (N=113) | Overall population (N=188) | ≥50% Responders (N = 77) | Non-responders (N =110) | Overall population (N=187) | |
Change from baseline to Week 12 | ||||||
 MMD | −12.2 (2.9) | −2.6 (4.3) | −6.6 (6.1) | −12.5 (4.6) | −2.2 (4.4) | −6.5 (6.8) |
 MSMD | −5.2 (5.2) | −1.8 (4.1) | −3.3 (4.9) | −6.9 (5.6) | −2.4 (3.9) | −4.3 (5.2) |
 HIT-6 | −10.0 (7.6) | −2.8 (5.1) | −5.7 (7.2) | −10.7 (8.0) | −1.7 (5.1) | −5.5 (7.9) |
 MIDAS total score | −29.1 (45.4) | −12.6 (41.5) | −19.5 (43.8) | −35.0 (45.2) | −5.8 (38.4) | −18.1 (43.7) |
 MSQ-RFP | 23.0 (19.4) | 6.0 (19.8) | 13.0 (21.3) | 25.7 (23.2) | 4.8 (16.2) | 13.7 (22.1) |
 MSQ-RFR | 29.7 (18.6) | 9.4 (19.8) | 17.7 (21.7) | 32.7 (23.7) | 8.2 (18.5) | 18.7 (24.1) |
 MSQ-EF | 30.5 (25.4) | 11.1 (26.7) | 19.1 (27.8) | 33.3 (27.2) | 6.3 (19.9) | 17.8 (26.8) |